AI-generated summary
The authors report a nonrandomized controlled trial of adjunctive near-infrared photobiomodulation therapy in 54 patients with Bell's palsy lasting more than 8 weeks, compared with a control group. They found statistically significant differences between groups on the House-Brackmann and Sunnybrook facial grading scales after 6 months, and suggest the therapy may relieve symptoms. The nonrandomized design limits causal conclusions.
- Participants
- 54
- Who or what was studied
- Patients with Bell's palsy with a duration of greater than 8 weeks, recruited at an outpatient otorhinolaryngology department in Beijing Tongren Hospital
- Wavelengths
- 808, 905 nm
- Limits stated in the abstract
- The trial was nonrandomized, with control and treatment groups recruited in different calendar years, and the abstract does not describe blinding or adjustment for these differences.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 905 nm, 808 nm
- Energy density (fluence)
- 8.35 J/cm2
- Power
- 1.2 W, 1 W, 200 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Near-infrared, Control group, Confidence interval, Trial registration, Primary outcome, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.